Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet

$ALC
Ophthalmic Goods
Health Care
Get the next $ALC alert in real time by email
  • SYSTANE PRO Preservative-Free (PF) is the longest lasting dry eye drop in the SYSTANE portfolio1
  • SYSTANE PRO PF is a one-of-a-kind multi-dose preservative-free triple action formula that hydrates, restores and protects all types of dry eyes1
  • SYSTANE PRO PF will be showcased at SECO 2025 as the latest addition to the SYSTANE line of products, the #1 global consumer brand of artificial tears2

Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of SYSTANE® PRO Preservative-Free (PF) as the latest over-the-counter eye drop in the company's dry eye portfolio. SYSTANE PRO PF is the longest lasting eye drop in the SYSTANE portfolio with a unique triple action, preservative-free formula for the temporary relief of burning and irritation due to dryness of the eye.1

Dry eye disease is one of the most common ocular surface disorders, affecting an estimated 45.5 million people in the United States and 1.5 billion globally.3 Developed exclusively to offer dry eye symptom relief, SYSTANE PRO PF is a one-of-a-kind formula that works to provide sustained hydration, restore tear film stability and protect against further irritation of dry eyes.

"We are proud to introduce SYSTANE PRO PF, the first and only multi-dose preservative-free triple action formula with hyaluronate, nano-sized lipids and HP-Guar that support the active ingredient giving patients long-lasting relief from the symptoms of dry eye," said Terry Kim, MD, Chief Medical Officer and Head of Global Medical Safety, Alcon. "This is another example of how Alcon is bringing innovation to the SYSTANE portfolio to address the needs of dry eye patients."

Patients with dry eyes often experience symptoms when moisture retention and tear stability are impacted by a variety of factors including aging, environment and digital device use.4 The unique formulation of SYSTANE PRO PF works to deliver long-lasting dry eye symptom relief for all types of dry eyes.1

"As an Eye Care Professional and global dry eye expert, I know that patients should benefit from the design of a triple action preservative-free formula that includes hyaluronate to address all types of dry eye," said Dr. Selina McGee, Founder and Chief Optometrist of Bespoke Vision in Edmond, Oklahoma. "SYSTANE PRO PF provides hydration and protection of the ocular surface and can also stabilize the lipid layer of the tear film to reduce evaporation and provide lasting dry eye relief for my patients."

The launch begins in the U.S. this month and will extend to additional markets in 2026. SYSTANE PRO PF will be featured at the SECO International meeting this week in Atlanta, Georgia.

To learn more about SYSTANE PRO PF, please visit Systane.com.

Important Information for the SYSTANE Family of Products

SYSTANE lubricant eye drops have been clinically proven to reduce the symptoms of dry eye, providing fast, long-lasting relief and comfort. SYSTANE is the #1 global consumer brand of artificial tears.2 SYSTANE COMPLETE provides symptom relief for people who suffer from evaporative dry eye, aqueous tear-deficient dry eye or mixed dry eye. SYSTANE ULTRA is designed for dry eye with aqueous deficient patients. SYSTANE BALANCE lubricant eye drops are designed specifically for patients with evaporative dry eye associated with meibomian gland dysfunction. SYSTANE HYDRATION gives long-lasting relief of dry eye symptoms for moderate or chronic sufferers or patients who are recovering from corneal or other eye surgery.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

References

  1. Alcon Data on File, 2025.
  2. IQVIA Consumer Health Customized Insights.
  3. Dry Eye Products Markets Report, Market Scope, 2023.
  4. Market Scope LLC. 2020 Dry Eye Products Report: A Global Market Analysis for 2019 to 2025. St. Louis, MO.

Connect with us on

Facebook

LinkedIn

Investor Relations

Daniel Cravens, Allen Trang

+ 41 589 112 110 (Geneva)

+ 1 817 615 2789 (Fort Worth)

investor.relations@alcon.com



Media Relations

Steven Smith

+ 41 589 112 111 (Geneva)

+ 1 817 551 8057 (Fort Worth)

globalmedia.relations@alcon.com

Get the next $ALC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALC

DatePrice TargetRatingAnalyst
3/25/2025Neutral → Buy
BofA Securities
1/24/2025$108.00 → $106.00Buy
Needham
1/10/2025Neutral → Buy
Redburn Atlantic
12/17/2024$103.00 → $108.00Buy
Needham
11/12/2024Buy
Needham
10/10/2024Sell → Neutral
Redburn Atlantic
9/10/2024Sector Perform → Outperform
RBC Capital Mkts
7/15/2024$65.00 → $85.00Underweight → Equal-Weight
Morgan Stanley
More analyst ratings

$ALC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities

    Clareon Vivity IOL provides an extended range of vision from distance to functional near with a monofocal visual disturbance profile1-3µ‖ Vivity, the world's leading EDOF, is now available on Alcon's Clareon material, providing presbyopia correction with exceptional† clarity and predictable refractive outcomes1,4-7 CE Marked countries will begin commercial rollout of Clareon Vivity and Clareon Vivity Toric from early Q2 2025; also available in AutonoMe automated pre-loaded delivery system in Q3 20258 Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that Vivity®, the most widely implanted9 extended depth of focus (EDOF)

    $ALC
    Ophthalmic Goods
    Health Care
  • Alcon Agrees to Acquire LENSAR, Inc.

    Acquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon's cataract equipment and technology portfolioNext generation technology will be expanded globally, improving the efficiency of cataract surgery GENEVA and ORLANDO, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ:LNSR), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced the companies have entered into a definitive merger agreement through which Alcon intends to acquire LENSAR. The acquisition includes ALLY Robotic Cataract Laser Treatment Sy

    $ALC
    $LNSR
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments
  • Alcon to Host 2025 Capital Markets Day

    Alcon (SIX/NYSE:ALC), the global leader in eye care, will host its 2025 Capital Markets Day on March 27, 2025, beginning at 8:00 a.m. CT. A live webcast of the event will be available at the following link: https://investor.alcon.com/news-and-events/events-and-presentations/event-details/2025/Alcons-2025-Capital-Markets-Day-2025-6w85_Spqte/default.aspx. Those wishing to participate should register and log on approximately 10 minutes before the start of the webcast. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical an

    $ALC
    Ophthalmic Goods
    Health Care

$ALC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ALC
SEC Filings

See more

$ALC
Leadership Updates

Live Leadership Updates

See more
  • Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

    Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

    $ALC
    $NARI
    $OCS
    $RXST
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

$ALC
Financials

Live finance-specific insights

See more
  • Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation

    Full-year 2024 sales of $9.8 billion, up 5%, or up 6% constant currency1 (cc) Full-year 2024 diluted EPS of $2.05, up 5% on a reported basis, or up 11% cc; core diluted EPS2 of $3.05 up 11% on a reported basis, or up 16% cc Generated record $2.1 billion of cash from operations in full-year 2024; record free cash flow3 of $1.6 billion, up 120% Announced share repurchase authorization to offset dilution from associate equity incentive plans Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2024. For the fourth quarter of 2024, sales were $2.5

    $ALC
    Ophthalmic Goods
    Health Care
  • Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation

    Third-quarter 2024 sales of $2.4 billion, up 6% on a reported and constant currency1 (cc) basis Third-quarter 2024 diluted EPS of $0.53, up 29%, or 32% cc; core diluted EPS2 of $0.81, up 23%, or 25% cc Generated $1.6 billion of cash from operations in the first nine months of 2024; record free cash flow3 of $1.3 billion, up $704 million, or 119% Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2024. For the third quarter of 2024, sales were $2.4 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarte

    $ALC
    Ophthalmic Goods
    Health Care
  • Alcon Reports Second-Quarter 2024 Results with Strong Growth in Implantables and Contact Lenses

    Record Q2 2024 sales of $2.5 billion, up 3%, or 6% constant currency1 (cc) Q2 2024 diluted EPS of $0.45, up 32%, or 47% cc; core diluted EPS2 of $0.74, up 7%, or 15% cc H1 2024 cash from operations of $871 million; free cash flow3 of $667 million, up $478 million, or 253% Received U.S. FDA clearance of Unity VCS/CS and PDUFA date for AR-15512 of May 30th, 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2024. For the second quarter of 2024, sales were $2.5 billion, an increase of 3% on a reported basis and 6% on a constant currency basis1, as

    $ALC
    Ophthalmic Goods
    Health Care

$ALC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more